Baseline covariates | Non IPT cohort | IPT cohort | Total | |
---|---|---|---|---|
N = 1548 | N = 374 | N = 1922 | ||
No. (%) | No. (%) | No. (%) | ||
Gender | Female | 848 (54.8) | 225 (11.768.2) | 1073 (55.8) |
Age group | 15 – 25 years | 333 (21.5) | 78 (20.9) | 411 (21.4) |
26 – 29 years | 238 (15.4) | 63 (16.8) | 301 (15.7) | |
30 – 34 years | 355 (22.9) | 94 (25.1) | 449 (23.4) | |
35 – 39 years | 268 (17.3) | 58 (15.5) | 326 (17.0) | |
40 – 99 years | 354 (22.9) | 81 (21.7) | 435 (22.6) | |
ART at baseline | No | 1307 (84.4) | 328 (87.7) | 1635 (85.1) |
Yes | 241 (15.6) | 46 (12.3) | 287 (14.9) | |
Cotrimoxazole (ever use)* | Yes | 1290 (83.3) | 341 (91.2) | 1631 (84.9) |
WHO stage of HIV disease* | Stage I | 141 (9.1) | 39 (10.4) | 180 (9.4) |
Stage II | 247 (16.0) | 78 (20.9) | 325 (16.9) | |
Stage III | 1000 (64.6) | 236 (63.1) | 1236 (64.3) | |
Stage IV | 160 (10.3) | 21 (5.6) | 181 (9.4) | |
WHO functional status* | Ambulatory | 590 (38.1) | 110 (29.4) | 700 (36.4) |
Bedridden | 99 (6.4) | 8 (2.1) | 107 (5.6) | |
Working | 859 (55.5) | 256 (68.4) | 1115 (58.0) | |
CD4* | 0 – 99 cells/mm3 | 477 (30.8) | 76 (20.3) | 553 (28.8) |
100 – 199 cells/mm3 | 561 (36.3) | 142 (38.0) | 703 (36.6) | |
200 - 349 cells/mm3 | 446 (28.8) | 145 (38.8) | 591 (30.8) | |
350 + cells/mm3 | 63 (4.1) | 11 (2.9) | 74 (3.9) | |
Body weight | < = 50 Kgs. | 726 (47.5) | 153 (41.6) | 879 (46.4) |
50-74 Kgs. | 763 (50.0) | 204 (55.4) | 967 (51.0) | |
75 + Kgs. | 38 (2.5) | 11 (3.0) | 49 (2.6) | |
Transfer in | yes | 160 (10.3) | 36 (9.6) | 196 (10.2) |
Point of entry to care (Entry from) | Referred from the same hospital | 1197 (77.3) | 296 (79.1) | 1493 (77.7) |
Self-referred | 29 (1.9) | 6 (1.6) | 35 (1.8) | |
Referred from other health facilities | 322 (20.8) | 72 (19.3) | 394 (20.5) | |
Outcomes | Censored | 1301 (84.0) | 363 (97.1) | 1664 (86.6) |
TB | 105 (6.8) | 5 (1.3) | 110 (5.7) | |
Death | 142 (9.2) | 6 (1.6) | 148 (7.7) | |
Composite outcome | TB or death | 247 (16.0) | 11 (2.9) | 258 (13.4) |